Anumeha Sheth, MD
Epilepsy · Hartford, CTNPI 1942514773
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by SK Life Science, Inc. at 27.9% of the total.
Across 41 payments — averaging $36.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$420
- UCB, Inc.$322
- Neurelis, Inc.$315
- Jazz Pharmaceuticals Inc.$207
- Amgen$64
- Sumitomo Pharma America, Inc.$38
- plus $140 from 7 others
What the payments were for
- Food & beverage$1,49399%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 13 | $420 |
| UCB, Inc. | 7 | $322 |
| Neurelis, Inc. | 4 | $315 |
| Jazz Pharmaceuticals Inc. | 5 | $207 |
| Amgen | 3 | $64 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $23 |
| Impel Pharmaceuticals Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| AbbVie | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Tonix Medicines, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few epilepsy providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AptiomEslicarbazepine Acetate | 54 | $152,225 |
| XcopriCenobamate | 43 | $67,604 |
| NayzilamMidazolam | 18 | $30,810 |
| KeppraLevetiracetam | 19 | $29,278 |
| Lacosamide | 179 | $22,563 |
| VimpatLacosamide | 17 | $22,197 |
| Lamotrigine ErLamotrigine | 34 | $15,080 |
| Carbamazepine ErCarbamazepine | 45 | $12,402 |
| Levetiracetam | 450 | $11,527 |
| CarbatrolCarbamazepine | 43 | $5,844 |
| Clobazam | 56 | $4,772 |
| Levetiracetam ErLevetiracetam | 68 | $4,149 |
| Divalproex Sodium | 38 | $3,641 |
| Oxcarbazepine | 38 | $2,596 |
| Carbamazepine | 50 | $2,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $420 | $67,60443 claims |
| UCB, Inc.Nayzilam, Vimpat | $322 | $53,00735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few epilepsy providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other epilepsy in Hartford
- Sarah Meira BenchayaHartford$2K
- Lisa KnopfHartford$1K
- Gabriel MartzHartford$878
- Swetha AdeHartford$876
- Yan ZhangHartford$186
- Maria Kristina DorotanNew Haven$3K
- Meghan WardNorwich$233
- Gordon BuchananNew Haven$182
- Nicole CassonNew Haven$34
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.